Leqvio and Finasteride Interaction: What Women Need to Know

The Short Answer: Is There a Real Interaction?

No clinically significant pharmacokinetic interaction between inclisiran and finasteride has been identified in the FDA labeling for either drug, in DDI databases, or in published primary literature as of mid-2025. The two drugs work through completely separate biological pathways and are handled by the body through different clearance mechanisms.

The clinical picture for women is more complicated than a single yes-or-no answer. You may be taking finasteride for female pattern hair loss, for PCOS-related hyperandrogenism, or for another androgen-driven condition, while inclisiran addresses cardiovascular risk from familial hypercholesterolemia or established ASCVD. Understanding why the interaction is low-risk, and what you still need to monitor, matters more than a blanket reassurance.

How Each Drug Is Cleared

Inclisiran is a small interfering RNA (siRNA) molecule. It does not rely on cytochrome P450 enzymes for metabolism. The FDA label for inclisiran confirms the drug is metabolized by nucleases into shorter nucleotide fragments, with minimal renal excretion of intact drug. It is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, and it does not interact with P-glycoprotein or major transporters.

Finasteride, by contrast, is metabolized primarily by CYP3A4, though this pathway is considered minor relative to overall clearance. It is not a meaningful inhibitor or inducer of CYP enzymes at therapeutic doses. Because inclisiran does not touch CYP3A4, there is no enzyme-level competition between these two drugs.

Pharmacodynamic Overlap: Androgen and Lipid Pathways

At a pharmacodynamic level, the story is more interesting than the pharmacokinetics alone suggest. Cholesterol is the biochemical precursor to all steroid hormones, including androgens. Dihydrotestosterone (DHT), the androgen that finasteride blocks from forming, is downstream of cholesterol in the steroidogenic cascade.

Inclisiran silences the gene encoding PCSK9 in hepatocytes, increasing LDL receptor recycling and driving LDL-C reductions of approximately 50% from baseline in the ORION-11 trial (N=1,561; LDL-C reduction 49.9% at day 510 vs. Placebo, p<0.001). Finasteride inhibits 5-alpha-reductase types 1 and 2, reducing conversion of testosterone to DHT by roughly 65-70% at the 5 mg dose and around 70% at the 1 mg dose in scalp tissue. These are parallel, not intersecting, mechanisms at any therapeutic concentration studied.

No published human data demonstrates that aggressive LDL-C lowering with inclisiran meaningfully alters circulating androgen levels in women. This is an area where evidence is genuinely thin, and the honest answer is that sex-hormone effects of aggressive PCSK9 inhibition in women have not been well characterized in dedicated trials.

Why Women Are Taking Both Drugs

Most conversations about finasteride and cardiovascular drugs assume a male patient. Women on finasteride are almost invisible in the cardiovascular literature, yet there are several distinct female clinical scenarios where you might be prescribed both drugs.

Post-Menopausal Women with ASCVD and Androgenic Alopecia

After menopause, estrogen levels fall sharply, relative androgen excess becomes physiologically prominent, and LDL-C typically rises. Female pattern hair loss (androgenetic alopecia) affects approximately 40% of women by age 70, and DHT-mediated follicular miniaturization is a key driver. Some dermatologists and endocrinologists prescribe finasteride 1-2.5 mg off-label in post-menopausal women who cannot become pregnant, precisely because teratogenicity risk is absent in this group.

Simultaneously, post-menopausal women with familial hypercholesterolemia or established cardiovascular disease may be candidates for inclisiran when statins plus ezetimibe have not achieved target LDL-C. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction supports adding PCSK9-targeting therapy in very-high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy. This is exactly the population where both drugs may appear on the same medication list.

Women with PCOS

PCOS affects 8-13% of reproductive-age women globally, making it the most common endocrine disorder in this life stage. Hyperandrogenism, insulin resistance, and dyslipidemia commonly occur together. Some women with PCOS-driven hirsutism or alopecia are prescribed finasteride off-label; the same women may have atherogenic dyslipidemia severe enough to warrant consideration of inclisiran in exceptional cases, though this is far less common in younger reproductive-age women than in post-menopausal women.

The evidence gap is substantial here. Women with PCOS were not included in the main ORION inclisiran trials as a defined subgroup.

Mechanism Deep-Dive: Why the Risk Is Low

Understanding the mechanistic reasoning is worth a few minutes of your time, because it tells you when to remain vigilant even in the absence of a formal interaction signal.

Inclisiran's Unusual Pharmacology

Inclisiran is a synthetic double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it specifically to hepatocytes via the asialoglycoprotein receptor. After subcutaneous injection, it reaches peak hepatic concentration within hours, is rapidly processed inside hepatocytes, and the intact molecule is essentially gone from systemic circulation within days. Peak plasma concentration occurs at approximately 4 hours post-dose, with a plasma half-life of roughly 9 hours for the intact molecule, even though the gene-silencing effect on PCSK9 lasts for 6 months.

This means that for the vast majority of the time inclisiran is exerting its effect, no intact drug is present in plasma to interact with other medications. Nuclease-derived metabolites are not pharmacologically active and do not inhibit drug-metabolizing enzymes.

Finasteride's CYP3A4 Pathway

Finasteride is absorbed orally, reaches peak plasma concentration in 1-2 hours, and is metabolized in the liver via CYP3A4 into two inactive metabolites. The FDA finasteride label notes no meaningful drug interactions with drugs that inhibit or induce CYP3A4 at the doses studied, though strong CYP3A4 inhibitors could theoretically raise finasteride exposure. Because inclisiran does not touch CYP3A4 at any point, this theoretical risk does not apply.

Plasma protein binding of finasteride is approximately 90%, but this is also irrelevant to inclisiran, which is hepatocyte-targeted and cleared before meaningful systemic competition occurs.

The P-Glycoprotein Question

P-glycoprotein (P-gp) is a transporter that affects the absorption and distribution of many drugs. Some have asked whether inclisiran might affect P-gp-transported drugs. The FDA label states clearly that inclisiran is neither a substrate nor an inhibitor of P-gp. Finasteride is also not meaningfully dependent on P-gp for its absorption or clearance. This channel of interaction is closed.

Sex-Specific Pharmacology: How Being a Woman Changes Things

Inclisiran Efficacy in Women

The ORION program enrolled women, though they were underrepresented. In ORION-9, which studied heterozygous familial hypercholesterolemia, women made up approximately 46% of participants. LDL-C reductions were consistent across sexes, with no statistically significant sex-by-treatment interaction reported. However, sex-stratified cardiovascular outcome data from inclisiran are not yet available from dedicated female cohorts, and this is a genuine evidence gap.

Body weight and body composition differ between men and women in ways that affect subcutaneous drug absorption and distribution volume. Inclisiran is dosed as a fixed 284 mg dose without weight adjustment per the FDA label. Whether leaner body composition or higher adiposity (more common in women with metabolic syndrome) alters the pharmacodynamic response has not been studied in sex-stratified pharmacokinetic analyses published as of 2025.

Finasteride in Women: Off-Label and Understudied

Finasteride's use in women is almost entirely off-label in the United States. The FDA has approved finasteride 5 mg (Proscar) only for benign prostatic hyperplasia in men, and finasteride 1 mg (Propecia) only for male pattern baldness. Off-label use in women with androgenic alopecia or PCOS-related hirsutism has a meaningful evidence base, but the trials are small. A 2020 systematic review in JAAD found that finasteride improved hair density in women with female pattern hair loss, but most studies included fewer than 100 participants.

Because clinical trials of finasteride in women are sparse, any interaction signal involving women specifically would be very unlikely to have been detected even if one existed.

Pregnancy, Lactation, and Contraception: Non-Negotiable Information

Finasteride is absolutely contraindicated in pregnancy. This is not a relative contraindication or a "discuss with your doctor" situation. Finasteride is FDA Pregnancy Category X: animal and human data demonstrate that exposure during male fetal development causes ambiguous genitalia and other anomalies of the external genitalia. Even handling crushed tablets carries a warning for pregnant women.

If you are of reproductive age and taking finasteride, you must use reliable contraception throughout the course of treatment and for at least one month after stopping. This is non-negotiable.

Inclisiran in Pregnancy

Inclisiran has no adequate, well-controlled studies in pregnant women. The FDA label advises that inclisiran should be discontinued when pregnancy is detected, given that lowering maternal LDL-C during fetal development may cause fetal harm, since cholesterol is required for fetal cell membrane synthesis and steroidogenesis. The long pharmacodynamic half-life of inclisiran (approximately 6 months of LDL-C lowering per dose) makes this a particularly important planning conversation: if you receive a dose and then become pregnant within months, LDL-C suppression continues well into the first trimester.

Women of reproductive age prescribed inclisiran should discuss the timing of doses relative to family planning with their cardiologist and OB-GYN.

Lactation

Neither inclisiran nor finasteride has adequate data on transfer into human breast milk. Finasteride's lipophilicity raises a theoretical concern for milk transfer, though no human lactation studies exist. The FDA label for finasteride does not provide lactation data because the drug was developed for a male indication. Inclisiran's GalNAc-conjugated siRNA structure would likely be degraded in the infant GI tract if ingested via breast milk, but this has not been confirmed in human studies. Both drugs should be considered incompatible with breastfeeding until further data are available.

Who This Combination Is Right For, and Who Should Pause

Likely Appropriate

Post-menopausal women with confirmed androgenic alopecia who are also on maximally tolerated statin therapy with residual LDL-C elevation above guideline targets represent the clearest group where both drugs make clinical sense together. In this group, finasteride teratogenicity is no longer a concern, and no pharmacokinetic interaction requires dose adjustment for either drug.

Women with familial hypercholesterolemia who have documented PCOS and are using finasteride for hirsutism or alopecia, and who are not pregnant or planning pregnancy in the near term, may also be candidates, provided strong contraception is in place and both prescribers are communicating.

Requires Careful Coordination

Women who are trying to conceive should not be on finasteride at all. If ASCVD risk is high enough to warrant inclisiran in a woman who is also trying to conceive, the cardiovascular and reproductive endocrinology teams need an explicit shared plan for drug timing and contraception.

Women with PCOS who are on finasteride and who have early-onset dyslipidemia severe enough to consider inclisiran at a young reproductive age represent an unusual and high-complexity case. Statins, dietary intervention, and ezetimibe should be exhausted before inclisiran is considered in reproductive-age women, partly because of the inclisiran pregnancy data gap and partly because the cardiovascular benefit of inclisiran in women under 45 without established ASCVD is not established by outcome trials.

Monitoring: What to Track When You Take Both

No special monitoring is required specifically because of a drug-drug interaction between inclisiran and finasteride, since none has been identified. Monitoring should follow the standard protocol for each drug independently.

For Inclisiran

• Fasting LDL-C at approximately 3 months after each dose (two doses are given: at day 1, day 90, and then every 6 months)
• Liver function tests are not routinely required per label, but hepatic disease may affect nuclease-mediated clearance
• Injection site reactions occur in approximately 8.2% of patients and are generally mild; note whether they are worsening between doses

For Finasteride in Women

• Serum total testosterone, free testosterone, and DHEA-S at baseline and at 3-6 months to confirm androgenic suppression is adequate
• Liver function tests annually given hepatic metabolism, particularly if other hepatotoxic drugs are co-prescribed
• Pregnancy test before initiating and reliable contraception confirmed throughout treatment
• Hair density assessment at 6 and 12 months using a standardized tool such as the Ludwig scale or trichoscopy

Leqvio's Broader Drug Interaction Profile: What Actually Matters

Because inclisiran's interaction risk with finasteride is minimal, women often ask about its interactions with drugs they are more commonly prescribed. The FDA label lists no formal drug interactions for inclisiran, but a few practical points apply.

Statins are almost always co-prescribed. No pharmacokinetic interaction exists with atorvastatin, rosuvastatin, or other statins. The ORION-10 trial was conducted largely in patients on background statin therapy without signal of interaction.

Oral contraceptives contain ethinyl estradiol and progestins, some of which are CYP3A4 substrates. Inclisiran does not alter CYP3A4 activity, so contraceptive efficacy is not affected by inclisiran. This is a clinically important point for reproductive-age women.

Hormone therapy (HT) used in perimenopause and menopause involves estradiol and progesterone or progestins with varied CYP profiles. Again, inclisiran's lack of CYP involvement means no relevant pharmacokinetic interaction is expected.

Levothyroxine, commonly prescribed in women given the 2:1 female-to-male prevalence of hypothyroidism, is not affected by inclisiran. Thyroid function should be monitored routinely regardless.

A Clinician's Framing for Shared Decision-Making

As Dr. Elena Vasquez, the WomanRx reviewing clinician for this article, notes: "The absence of a pharmacokinetic signal between inclisiran and finasteride is reassuring, but it does not replace the conversation about why each drug is on the list, what stage of life the woman is in, and whether she is protected against pregnancy if she is taking finasteride. The drug interaction question is almost always the easy part. The harder part is making sure both prescribers know about both drugs and agree on the monitoring plan."

This framing captures the clinical reality for women on complex regimens. Fragmented specialty care, where a cardiologist prescribes inclisiran and a dermatologist prescribes finasteride without shared awareness, is a real risk that drug interaction databases cannot solve.

FAQs